Back to top

B-PROTECTED Logo

 

 

 

 

 

 

 

 

 

 

MTN-043, or B-PROTECTED, is a Phase IIIb open-label study that evaluated the safety and acceptability of the monthly dapivirine ring, which is under regulatory review in several African countries, and Truvada as daily oral PrEP in women who are breastfeeding, a time of heightened vulnerability for acquiring HIV. The study enrolled 200 breastfeeding mothers and their 6- to 12-week-old babies at four sites in Malawi, South Africa, Uganda and Zimbabwe. Women used their assigned product – oral PrEP or the dapivirine ring – for three months and were followed for an additional two weeks. Researchers assessed how much drug from Truvada and the dapivirine ring passes into breastmilk and how much passes to the baby after breastfeeding, and measured the effects, if any, this may have had on their health. B-PROTECTED was began in September 2020 and completed all follow-up in November 2021. Results are anticipated mid-2022.


Where we are with the DELIVER and B-PROTECTED studies: 3 things you need to know (infographic)
20-August-2021
 

Questions and Answers - The DELIVER and B-PROTECTED Studies
21-July-2021

 

The DELIVER and B-PROTECTED Studies: Preventing HIV in Pregnant and Breastfeeding Women

08-September-2020

 

Researchers begin safety study of dapivirine ring and oral PrEP in breastfeeding women
31-August-2020

 

Video about DELIVER and B-PROTECTED in English
DELIVER and B-PROTECTED Video Image

 

 

 

 

 

 

 


Video about DELIVER and B-PROTECTED in Zulu
DELIVER and B-PROTECTED Video in Zulu

 

 

 

 

 

 

 

 

Video about DELIVER and B-PROTECTED in Luganda
DELIVER and B-PROTECTED Video Image in Luganda

 

 

 

 

 

 

 

 

Video about DELIVER and B-PROTECTED in Shona
DELIVER and B-PROTECTED Video Image in Shona

 

 

 

 

 

 

 

Video about DELIVER and B-PROTECTED in Chichewa
DELIVER and B-PROTECTED Video Image in Chichewa

 

 

 

 

 

 

 

See Also

MTN-043 Study Page (B-PROTECTED)

 

MTN-042 (DELIVER)